National Foundation For Cancer Research in Baltimore: Where Research Funding Meets Patient Support
The National Foundation For Cancer Research (NFCR) is a nonprofit organization headquartered in Baltimore that funds laboratory-based cancer research and supports patient education, operating without the direct clinical care of an oncology practice but functioning as a research-advocacy hybrid that shapes how Baltimore-area cancer patients access funding information and connect to treatment advances.
What the National Foundation For Cancer Research actually does
NFCR operates as a grant-making and advocacy organization rather than a clinic or treatment center. Since its establishment in Baltimore in 1981, the foundation has awarded over $200 million to peer-reviewed cancer research projects, with approximately 85 cents of every donation directed toward research and programs (verified annually in its public tax filings). The organization maintains a small Baltimore-based staff and conducts no oncology treatment itself; instead, it functions as a bridge between researchers seeking funding and patients seeking clarity about clinical trials, treatment options, and survivorship resources.
The foundation focuses on "revolutionary" research approaches, though its grants typically support academic laboratories and medical centers rather than pharmaceutical companies or for-profit entities. This distinction matters for Baltimore patients: NFCR-funded research often leads to clinical trials at University of Maryland Medical Center, Johns Hopkins, and Mercy Medical Center, the three major oncology centers serving the city.
Research areas and funding priorities
NFCR distributes grants in breast cancer, ovarian cancer, skin cancer, prostate cancer, colorectal cancer, and pediatric cancers, as well as emerging areas like immunotherapy and personalized medicine. The foundation published its 2024 funding priorities on its website; breast and ovarian cancer research received the largest allocation. For Baltimore residents enrolled in clinical trials at local institutions, understanding which trials are NFCR-backed can clarify the research rigor and funding stability of a given study.
The foundation does not accept direct patient donations for personal treatment and does not provide individual financial assistance for copayments or treatment costs. Patient-facing services include a telephone helpline and online resource library about cancer types, clinical trial searches, and referrals to local oncology programs.
How NFCR compares to other Baltimore cancer research and advocacy organizations
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, located within Baltimore, operates its own research funding mechanisms and clinical trials through Hopkins' internal structure and does not distribute external grants. Patients treated at Johns Hopkins access research opportunities on campus; patients treated elsewhere may pursue Johns Hopkins trials by referral.
The American Cancer Society (ACS), also active in Baltimore, operates as a separate 501(c)(3) organization focused on fundraising for research, education, and patient services. The ACS distributes grants to researchers nationally and locally but does not focus exclusively on laboratory grants; it also funds navigator programs and educational events in Baltimore-area communities. NFCR's niche is specifically laboratory-based research funding rather than the broader educational and supportive-care mission of the ACS.
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, the University of Maryland's oncology research hub in Baltimore, manages clinical trials and patient care through its own institution but does not function as an external grant distributor. NFCR-funded researchers may conduct studies at Greenebaum; patients should ask their oncologist whether their trial receives NFCR support, as this may clarify the funding source and long-term stability of the program.
When NFCR matters and when it does not
NFCR is most useful for Baltimore patients who are researching a specific cancer type or exploring clinical trial options and want to understand who is funding the underlying science. Patients already enrolled in trials at Johns Hopkins, University of Maryland, or Mercy Medical Center may benefit from NFCR's patient education materials to learn more about the biological rationale for their treatment. The organization is not a substitute for an oncologist or oncology center and cannot provide medical advice, treatment, or scheduling.
NFCR is not useful for patients seeking financial assistance with treatment costs, medication copayments, or travel to appointments. Patients in that situation should contact their oncology center's financial navigation team, local chapters of the ACS or CancerCare, or organizations like Patient Advocate Foundation.
How to access NFCR resources from Baltimore
NFCR operates a toll-free hotline at 1-800-4-CANCER (which directs to the National Cancer Institute; NFCR's direct number is 410-992-5162) and maintains a website with searchable databases of clinical trials in Maryland and nationwide. The foundation does not require an appointment and does not charge for educational materials or telephone guidance. Response times for calls or email inquiries are typically one to three business days.
Location and contact logistics
NFCR maintains its headquarters at 4600 East-West Highway in Bethesda, Maryland, approximately 45 minutes north of central Baltimore by car via Interstate 495. The Baltimore office, if it operates a separate walk-in location, is not listed as a patient-facing service point. All patient inquiries are handled remotely by phone or email. Donors and researchers interested in NFCR's grants may attend annual meetings held in Baltimore or Bethesda; dates and locations are posted quarterly on the website.
The foundation accepts donations online, by mail, and over the phone year-round. No appointment is required to access educational materials or the helpline.
NFCR's role is specific to Baltimore's research ecosystem: it funds the science that eventually reaches Hopkins, Maryland, and Mercy oncology programs. Patients should think of it as a transparency and education tool rather than a treatment provider or direct financial resource.
